John Curnutte, M.D., currently serves as Portola Pharmaceutical’s Executive Vice President, Research and Development. He is also an adjunct clinical professor of pediatrics at Stanford University School of Medicine and a member of the medical staff, where he continues to consult on patients with primary immunodeficiencies. Prior to joining Portola, Dr. Curnutte served as Chief Executive Officer of 3-V Biosciences, a private start-up company founded in 2007 with the goal of developing host-directed antiviral small molecules. Before that, he served as President at Schering-Plough Biopharma (formerly DNAX Research Institute and now Merck Research Laboratories), where he led the drug discovery and early development efforts for biologic therapeutics. During his time with Schering-Plough, eight therapeutic entities progressed into development. Earlier in his career, he held several senior management positions at Genentech during which he oversaw that company’s immunology discovery program. Prior to Genentech, Dr. Curnutte was a tenured faculty member at The Scripps Research Institute, pursuing basic and clinical research in inflammation biochemistry and the molecular genetics of congenital immune deficiencies. Dr. Curnutte is additionally a member of the board of directors of diaDexus, Inc., a company focused on cardiovascular diagnostics.
Dr. Curnutte received his B.S. in biochemistry and molecular biology from Harvard University and an M.D. and a Ph.D. in biological chemistry from Harvard Medical School.